Screening and diagnosis of primary aldosteronism

References

• Conn JW, Cohen EL, Rovner DR et al. Normokalemic primary aldosteronism: a detectable cause of curable ‘essential’ hypertension. JAMA193, 200–206 (1965).
   PubMed Web of Science ®Google Scholar
• Conn JW. Plasma renin activity in primary aldosteronism. Importance in differential diagnosis and in research of essential hypertension. JAMA190, 222–225 (1964).
   PubMed Web of Science ®Google Scholar
• Kaplan NM. Commentary on the incidence of primary aldosteronism. Current estimations based on objective data. Arch. Intern. Med.123, 152–155 (1969).
   Google Scholar
• Biglieri EG, Kater CE. Disorders of the adrenal cortex. In: Internal Medicine (3rd Edition). Stein JH (Ed.). Little Brown, MA, USA 2188–2207 (1991).
   Google Scholar
• Lim PO, Dow E, Brennan G, Jung RT et al. High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J. Hum. Hypertens.14, 311–315 (2000).
   PubMed Web of Science ®Google Scholar
• Fardella CE, Mosso L, Gomez-Sanchez C et al. Primary hyperaldosteronism in essential hypertensive: prevalence, biochemical profile, and molecular biology. J. Clin. Endocrinol. Metab.85, 1863–1867 (2000).
   PubMed Web of Science ®Google Scholar
• Rossi GP, Bernini G, Caliumi C et al. for the PAPY Study Investigators: a prospective study of the prevalence of primary aldosteronism in 1125 hypertensive patients. J. Am. Coll. Cardiol.48, 2293–2300 (2006).
   PubMed Web of Science ®Google Scholar
• Mosso L, Carvajal C, Gonzalez A et al. Primary aldosteronism and hypertensive disease. Hypertension42(2), 161–165 (2003).
   PubMed Web of Science ®Google Scholar
• Calhoun DA, Nishizaka MK, Zaman MA et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension40(6), 892–896 (2002).
   PubMed Web of Science ®Google Scholar
• Brown NJ. Aldosterone and end-organ damage. Curr. Opin. Nephrol. Hypertens.14(3), 235–241 (2005).
   PubMed Web of Science ®Google Scholar
• McMahon GT, Dluhy RG. Glucocorticoid-remediable aldosteronism. Arq. Bras. Endocrinol. Metabol.48(5), 682–686 (2004).
   Google Scholar
• Jackson RV, Lafferty A, Torpy DJ et al. New genetic insights in familial hyperaldosteronism. Ann. NY Acad. Sci.970, 77–88 (2002).
   PubMedGoogle Scholar
• Rich GM, Ulick S, Cook S et al. Glucocorticoid-remediable aldosteronism in a large kindred: clinical spectrum and diagnosis using a characteristic biochemical phenotype. Ann. Intern. Med.116(10), 813–820 (1992).
   PubMed Web of Science ®Google Scholar
• Sartori M, Calo LA, Mascagna V et al. Aldosterone and refractory hypertension: a prospective cohort study. Am J. Hypertens.19(4), 373–379 (2006).
   Google Scholar
• Mantero F, Terzolo M, Arnaldi G et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J. Clin. Endocrinol. Metab.85(2), 637–644 (2000).
   PubMed Web of Science ®Google Scholar
• Hiramatsu K, Yamada T, Yukimura Y et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch. Intern. Med.141(12), 1589–1593 (1981).
   PubMed Web of Science ®Google Scholar
• Giacchetti G, Ronconi V, Lucarelli G et al. Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol. J. Hypertens.24(4), 737–745 (2006)
   PubMedGoogle Scholar
• Mulatero P, Rabbia F, Milan A et al. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension40(6), 897–902 (2002).
   PubMed Web of Science ®Google Scholar
• Seiler L, Rump LC, Schulte-Mönting J et al. Diagnosis of primary aldosteronism: value of different screening parameters and influence of antihypertensive medication. Eur. J. Endocrinol.150, 329–337 (2004).
   PubMed Web of Science ®Google Scholar
• Schirpenbach C, Reincke M. Screening for primary aldosteronism. Best Pract. Res. Clin. Endocrinol. Metab.20(3), 369–384 (2006).
   PubMed Web of Science ®Google Scholar
• Ferrari P, Shaw SG, Nicod J et al. Active renin versus plasma renin activity to define aldosterone-to-renin ratio for primary aldosteronism. 22(2), 377–381 (2004).
   Google Scholar
• Stowasser M, Gordon RD, Rutherford JC et al. Diagnosis and management of primary aldosteronism. J. Renin Angiotensin Aldosterone Syst.2(3), 156–169 (2001).
   Google Scholar
• Lim PO, Farquharson CA, Shiels P, Jung RT, Struthers AD, MacDonald TM. Adverse cardiac effects of salt with fludrocortisone in hypertension. Hypertension37(3), 856–861 (2001).
   PubMed Web of Science ®Google Scholar
• Holland OB, Brown H, Kuhnert L et al. Further evaluation of saline infusion for the diagnosis of primary aldosteronism. Hypertension6(5), 717–723 (1984).
   PubMed Web of Science ®Google Scholar
• Hiramatsu K, Yamada T, Yukimura Y et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch. Intern. Med.141(12), 1589–1593 (1981).
   PubMed Web of Science ®Google Scholar
• Mulatero P, Stowasser M, Loh KC et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J. Clin. Endocrinol. Metab.89(3), 1045–1050 (2004).
   PubMed Web of Science ®Google Scholar
• Arteaga E, Klein R, Biglieri EG. Use of the saline infusion test to diagnose the cause of primary aldosteronism. Am. J. Med.79(6), 722–728 (1985).
   Google Scholar
• Gordon RD, Stowasser M, Tunny TJ et al. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin. Exp. Pharmacol. Physiol.21(4), 315–318 (1994).
   PubMed Web of Science ®Google Scholar
• Rossi GP, Belfiore A, Bernini G et al.; for the PAPY Study Investigators. Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosterone-producing adenoma. J. Hypertens.25(7), 1433–1442 (2007).
   Google Scholar
• Mulatero P, Milan A, Fallo F et al. Comparison of confirmatory tests for the diagnosis of primary aldosteronism. J. Clin. Endocrinol. Metab.91(7), 2618–2623 (2006).
   Google Scholar
• Mantero F, Fallo F, Opocher G et al. Effect of angiotensin II and converting enzyme inhibitor (captopril) on blood pressure, plasma renin activity and aldosterone in primary aldosteronism. Clin. Sci.61(Suppl. 7), 289s–293s (1981).
   PubMed Web of Science ®Google Scholar
• Agharazii M, Douville P, Grose JH et al. Captopril suppression versus salt loading in confirming primary aldosteronism. Hypertension37(6), 1440–1443 (2001).
   PubMed Web of Science ®Google Scholar
• Rossi GP, Belfiore A, Bernini G et al.; for the Primary Aldosteronism Prevalence in Italy Study Investigators. Comparison of the captopril and the saline infusion test for excluding aldosterone-producing adenoma. Hypertension50(2), 424–431 (2007).
   Google Scholar
• Rossi GP. Surgically correctable hypertension caused by primary aldosteronism. Best Pract. Res. Clin. Endocrinol. Metab.20(3), 385–400 (2006).
   Google Scholar
• Young WF, Stanson AW, Thompson GB et al. Role for adrenal venous sampling in primary aldosteronism. Surgery136, 1227–1235 (2004).
   PubMed Web of Science ®Google Scholar
• Nomura K, Kusakabe K, Maki M, Ito Y, Aiba M, Demura H. Iodomethylnorcholesterol uptake in an aldosteronoma shown by dexamethasone-suppression scintigraphy: relationship to adenoma size and functional activity. J. Clin. Endocrinol. Metab.71, 825–830 (1990).
   Google Scholar
• Mattsson C, Young WF. Primary aldosteronism: diagnostic and treatment strategies. Nat. Clin. Pract. Nephrol.2(4), 198–208 (2006).
   PubMedGoogle Scholar
• Young WF Jr, Stanson AW, Grant CS et al. Primary aldosteronism: adrenal venous sampling. Surgery120, 913–919 (1996).
   Google Scholar
• Rossi GP, Sacchetto A, Chiesura-Corona M et al. Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic resonance findings: results in 104 consecutive cases. J. Clin. Endocrinol. Metab.86, 1083–1090 (2001).
   PubMed Web of Science ®Google Scholar
• Magill SB, Raff H, Shaker JL et al. Comparison of adrenal vein sampling and computed tomography in the differentiation of primary aldosteronism. J. Clin. Endocrinol. Metab.86, 1066–1071 (2001).
   PubMed Web of Science ®Google Scholar
• Gordon RD. Primary aldosteronism. J. Endocrinol. Invest.18, 495–511 (1995).
   PubMed Web of Science ®Google Scholar
• Weinberger MH, Grim CE, Hollifield JW et al. Primary aldosteronism: diagnosis, localization and treatment. Ann. Intern. Med.90, 386–395 (1979).
   PubMed Web of Science ®Google Scholar
• Carr CE, Cope C, Cohen DL et al. Comparison of sequential versus simultaneous methods of adrenal venous sampling. J. Vasc. Interv. Radiol.15(11), 1245–1250 (2004).
   Google Scholar
• Blumenfeld J, Sealey J, Schlussel Y et al. Diagnosis and treatment of primary aldosetronism. Ann. Intern. Med.121(11), 877–885 (1994).
   PubMed Web of Science ®Google Scholar
• Plamondon I, Agharazii M, Douville P, Lebel M. Morning plasma aldosterone predicts the subtype of primary aldosteronism independent of sodium intake. Clin. Exp. Hypertens.29(2), 127–134 (2007).
   PubMed Web of Science ®Google Scholar
• McMahon GT, Dluhy RG. Glucocorticoid-remediable aldosteronims. Cardiol. Rev.12, 44–48 (2004).
   PubMedGoogle Scholar